References – Diabetic Biomarker

The Invention policy is based on the following References.

Inventor Dr. Mehmet Ali SÖYLEMEZ discovered first time, the utility of the biomarker PROCALCITONIN in DIABETES MELLITUS. More than 49 peer reviewed* publications have followed, substantiating PROCALCITONIN as one of the most promising biomarker tools for DIABETES MELLITUS of healthcare. Please see the papers…

1-SÖYLEMEZ MEHMET ALİ., A Novel Mechanism between Type II Diabetes Mellitus and Procalcitonin Gene Expression;

Molecular Therapy 11:S346-S346 · May 2005. AMERICAN SOCIETY OF GENE THERAPY 8th Annual Meeting • June 1 – 5, 2005 • St. Louis, MISSOURI, UNITED STATES OF AMERICA. DOI: https://doi.org/10.1016/j.ymthe.2005.07.437

2- SÖYLEMEZ MEHMET ALİ., A Novel Mechanism between Diabetes Mellitus Complications and Procalcitonin Gene Expression ;

Molecular Therapy 13:S86-S86 · May 2006. AMERICAN SOCIETY OF GENE THERAPY 9th Annual Meeting •, BALTIMORE, MARYLAND. UNITED STATES OF AMERICA. DOI: https://doi.org/10.1016/j.ymthe.2006.08.250

3- Plasma procalcitonin is associated with obesity, insulin resistance, and the metabolic syndrome.

Abbasi A, Corpeleijn E, Postmus D, Gansevoort RT, de Jong PE, Gans RO, Struck J, Hillege HL, Stolk RP, Navis G, Bakker SJ. J Clin Endocrinol Metab. 2010 Sep;95(9):E26-31. doi: 10.1210/jc.2010-0305. Epub 2010 Jun 9.

4- Plasma procalcitonin and risk of type 2 diabetes in the general population.

Abbasi A, Corpeleijn E, Postmus D, Gansevoort RT, de Jong PE, Gans RO, Struck J, Hillege HL, Stolk RP, Navis G, Bakker SJ. Diabetologia. 2011 Sep;54(9):2463-5. DOI: 10.1007/s00125-011-2216-3.

5- Can procalcitonin predict bone infection in people with diabetes with infected foot ulcers? A pilot study.

Mutluoğlu M, Uzun G, İpcioğlu OM, Sildiroglu O, Özcan Ö, Turhan V, Mutlu H, Yildiz S.Diabetes Res Clin Pract. 2011 Oct;94(1):53-6. doi:10.1016/j.diabres.2011.05.023. Epub 2011 Jun 11.

6- Relationship between cutaneous glycometabolic disorders and cutaneous neuropathy in diabetic rats].

Chen B, Niu YW, Xie T, Miao MY, Tian M, Ji XY, Qing C, Lu SL. Zhonghua Shao Shang Za Zhi. 2011 Apr;27(2):139-44.

7- 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections

Benjamin A Lipsky¹, Anthony R Berendt, Paul B Cornia, James C Pile, Edgar J G Peters, David G Armstrong, H Gunner Deery, John M Embil, Warren S ; Infectious Diseases Society of America Clin Infect Dis 2012 Jun;54(12):e132-73. doi: 10.1093/cid/cis346

8- Plasma procalcitonin and the risk of cardiovascular events: A prospective population-based study.

J Intern Med 2012;272(5):484-91. Schiopu A, Hedblad B, Engström G, Struck J, Morgenthaler NG, Melander O.

9- 25-OH-Vitamin D and procalcitonin levels after correction of acute hyperglycemia.

Aksu NM¹, Aksoy DY, Akkaş M, Yilmaz H, Akman C, Yildiz BO, Ozmen MM, Usman A.Med Sci Monit. 2013 Apr 12;19:264-8. doi: 10.12659/MSM.883880.

10– The value of procalcitonin measurement in localized skin and skin structure infection, diabetic foot infections, septic arthritis and osteomyelitis.

Saeed K, Ahmad N, Dryden M. Expert Rev Mol Diagn. 2014 Jan;14(1):47-54. doi: 10.1586/14737159.2014.864238. Epub 2013 Dec 2. Review. PMID:24308337.

11- Can procalcitonin be an accurate diagnostic marker for the classification of diabetic foot ulcers?

Int J Endocrinol Metab. 2014 Jan 5;12(1):e13376. doi: 10.5812/ijem.13376. eCollection 2014 Jan. Nematollah Jonaidi Jafari¹, Mahdi Safaee Firouzabadi¹, Morteza Izadi¹, Mohammad Sadegh Safaee Firouzabadi², Amin Saburi³

12- Higher procalcitonin level in diabetic nephropathy patients compared with healthy volunteers].

Wan ZM, Chen WY, Lu ML, Zhou HT, Gao YL, Zhang C, Han G, Tang XL, Huang XD.Sichuan Da Xue Xue Bao Yi Xue Ban. 2014 May;45(3):442-6. PMID:24941814.

13- Recent Advances in Detection of AGEs: Immunochemical, Bioanalytical and Biochemical Approaches

Jalaluddin Mohd.Ashraf et al.., IUBMB Life 2015 Dec;67(12):897-913. doi: 10.1002/iub.1450. Epub 2015 Nov 23.

14– Inflammation biomarkers and mortality prediction in patients with type 2 diabetes (ZODIAC-27).

Landman GW, et al., Atherosclerosis. 2016 Jul;250:46-51. doi: 10.1016/j.atherosclerosis.2016.04.015. Epub 2016 Apr 27.

15– The Role of Biomarkers to Diagnose Diabetic Foot Osteomyelitis. A Meta-analysis.

Victoria van Asten SA, et al., Curr Diabetes Rev. 2016;12(4):396-402.

16- ASSOCIATION OF SERUM PROCALCITONIN (PCT) and HIGH-SENSITIVITY C-REACTIVE PROTEIN (hs-CRP) LEVELS with INSULIN RESISTANCE and OBESITY in TYPE 2 EGYPTIAN DIABETIC PATIENTS.

AYAT I. GHANEM and MOHSEN KHALID, M.D. Med. J. Cairo Univ. Vol.84, No.1, September: 1165-1171, 2016.

17- Procalcitonin levels and other biochemical parameters in patients with or without diabetic foot complications.

Al-Shammaree SAW et al., J Res Med Sci. 2017 Aug 16;22:95. doi: 10.4103/jrms.JRMS_906_16. eCollection 2017.

18– Concentration of acute phase factors in vitreous fluid in diabetic macular edema.

Kimura K, Orita T, Kobayashi Y, Matsuyama S, Fujimoto K, Yamauchi K. Jpn J Ophthalmol. 2017 Nov;61(6):479-483. doi: 10.1007/s10384-017-0525-x. Epub 2017 Jul 28.

19- Role of procalcitonin in infected diabetic foot ulcer.

Park JH, etal.,Diabetes Res Clin Pract. 2017 Jun;128:51-57. doi: 10.1016/j.diabres.2017.04.008. Epub 2017 Apr 13.

20– Procalcitonin as a Biomarker for Predicting Amputation Level in Lower Extremity Infections.

Reiner MM,et al.,J Foot Ankle Surg. 2017 May – Jun;56(3):484-491. doi: 10.1053/j.jfas.2017.01.014. Epub 2017 Mar 22.

21- Role of biomarkers in predicting diabetes complications with special reference to diabetic foot ulcers.

Pichu S, et al.,Biomark Med. 2017 Apr;11(4):377-388. doi: 10.2217/bmm-2016-0205. Epub 2017 Mar 14. Review.

22– The value of inflammatory markers to diagnose and monitor diabetic foot osteomyelitis.

Van Asten SA, et al., Int Wound J. 2017 Feb;14(1):40-45. doi: 10.1111/iwj.12545. Epub 2015 Dec 3.

23- The role of procalcitonin as a marker of diabetic foot ulcer infection.

Massara M, et al., Int Wound J. 2017 Feb;14(1):31-34. doi: 10.1111/iwj.12536. Epub 2015 Oct 28.

24– Potential of circulatory procalcitonin as a biomarker reflecting inflammation among South Indian diabetic foot ulcers.

Umapathy D etal., J Vasc Surg. 2018 Apr;67(4):1283-1291.e2. doi: 10.1016/j.jvs.2017.02.060. Epub 2017 Jul 21.

25- Procalcitonin levels and other biochemical parameters in patients with or without diabetic foot complications

Shatha Abdul Wadood AL-Shammaree et al., J Res Med Sci. 2017; 22: 95. PMC5583618.

26- CLINICAL SIGNIFICANCE OF PROCALCITONIN AND C-REACTIVE PROTEIN IN THE PREDICTION OF CARDIOVASCULAR COMPLICATIONS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS.

HANAA H AHMED et al., Asian Journal of Pharmaceutical and clinical research (AJPCR) VOL 10 ISSUE 9 SEPTEMBER 2017 297-306. Research Article. https://doi.org/10.22159/ajpcr.2017.v10i9.19524.

27- [АNALYSIS OF LETHALITY IN COMPLICATED DIABETIC FOOT SYNDROME AND SEPSIS]

O V Тrybushnyi, S D Shapoval, I L Savon, V Novak Klin Khir. 2017;(1):58-60.

28- Procalcitonin and proinflammatory parameters in diabetic foot infection as new predictive factor .

Shler Gh. Raheem 1, Ruqaya M. Al-Barzinji, Husham Y. Mansoor and Ali A. Al-Dabbagh ; Department of Microbiology and Department of Surgery, Hawler Medical University, IRAQ 6th International Conference and Workshops on Basic and Applied SciencesAIP Conf. Proc.1888, 020043-1–020043-9; https://doi.org/10.1063/1.5004320

29- Procalcitonin as a diagnostic and prognostic marker in diabetic foot infection. A current literature review.

Velissaris D et al., Rom J Intern Med. 2018 Mar 1;56(1):3-8. doi: 10.1515/rjim-2017-0039.

30- Heart failure and inflammation-related biomarkers as predictors of new-onset diabetes in the general population.

Suthahar N¹, Meijers WC¹, Brouwers FP¹, Heerspink HJL², Gansevoort RT³, van der Harst P¹, Bakker SJL³, de Boer RA⁴.Int J Cardiol. 2018 Jan 1;250:188-194. doi: 10.1016/j.ijcard.2017.10.035. Epub 2017 Oct 16.

31- Role of Procalcitonin As an Inflammatory Marker in a Sample of Egyptian Children with Simple Obesity.

Open Access Maced J Med Sci. 2018 Aug 20; 6(8): 1349–1353. Ghada M. El Kassas,¹ Manal A. Shehata,^1,* Maged A. El Wakeel,¹ Ahmed F. Amer,¹ Fatma A. Elzaree,¹ Marwa K. Darwish,² and Marwa F. Amer³

32- Moderate increase of serum levels of procalcitonin in diabetic ketoacidosis.

Neth J Med. 2018 Dec;76(10):454. A Cipriano¹, E Rebelos, N Park, M Santini

33- Serum procalcitonin levels as a biomarker for diagnosis of gestational diabetes mellitus

Süleyman Baldane, Süleyman Hilmi İpekci, Ayşegül Kebapcılar, Sedat Abuşoğlu, Bahadır Öztürk, Ali Ünlü, Çetin Çelik, Levent Kebapcılar. Selçuk Üniversitesi Tıp Fakültesi; İç Hastalıkları Anabilim Dalı, Endokrinoloji ve Metabolizma Hastalıkları Bilim Dalı, KONYA, TURKEY. Cukurova Medical Journal 2018;43(1):62-66 https://doi.org/10.17826/cumj.340258

34- Redefined clinical spectra of diabetic foot syndrome.

Nawaf J Shatnawi¹, Nabil A Al-Zoubi¹, Hasan Hawamdeh², Yousef S Khader³, Abd El-Karim Omari¹, Muhammad R Khammash . Vasc Health Risk Manag. 2018 Oct 18;14:291-298. doi: 10.2147/VHRM.S169502.

35- Role of Procalcitonin as a Predictor of Clinical Outcome in Acute Diabetic Foot Infections: A Prospective Study.

Adlyne R Asirvatham 1, Usha Menon 2, Praveen V Pavithran 2, Jayakumar R Vasukutty 3, Harish Kumar 2, Nisha Bhavani 2, Arun Menon 2, Vasantha Nair 2, Vivek Lakshmanan 2, Ajit K Varma 4, Mangalanandan T Sukumaran 2, Arun Bal 2 Indian J Endocrinol Metab. Jan-Feb 2019;23(1):122-127. doi: 10.4103/ijem.IJEM_525_18.

36– Marked elevation of plasma Procalcitonin levels in patients with diabetic ketoacidosis: A possible useful diagnostic biomarker.

Anno T, Shigemoto R, Kawasaki F et al, Diabetes Metab. 2019 Jun 4. pii: S1262-3636(19)30089-8. doi: 10.1016/j.diabet.2019.05.006.

37- Gestational diabetes mellitus increases the baseline level of procalcitonin in maternal blood but not in umbilical cord blood in late pregnancy: A retrospective case-controlled study.

Ma Y, Ye W, Tang Y.Medicine ; Baltimore, MARYLAND, UNITED STATES Of AMERICA. 2019 Mar;98(11):e14914. doi: 10.1097/MD.0000000000014914.

38- Predictive value of procalcitonin for infection of patients with type-2 diabetes mellitus.

Exp Ther Med 2019 Jul;18(1):722-728. doi: 10.3892/etm.2019.7611. Epub 2019 May 24. Xinshui Wang,^1,* Yanbei Sun,^2,* and Xiaonan Shao³

39- Pro-Calcitonin, Erythrocyte Sedimentation Rate and C – reactive Protein in Predicting Diabetic Foot Ulcer Characteristics; a Cross Sectional Study.

Arch Acad Emerg Med. 2019 Jul 10;7(1):37. eCollection 2019. Fahimeh Hadavand¹, Atefeh Amouzegar², Hessam Amid¹

40- Procalcitonin Is a Prognostic Marker of Hospital Outcomes in Patients with Critical Limb Ischemia and Diabetic Foot Infection.

Journal of Diabetes Research Volume 2019, Article ID 4312737, 5 pages https://doi.org/10.1155/2019/4312737 Marco Meloni,¹ Valentina Izzo,¹ Laura Giurato,¹ Enrico Brocco,² Michele Ferrannini,³ Roberto Gandini,⁴ and Luigi Uccioli^1,2

41- Serum Procalcitonine level in diabetic foot patients.

Nature and Science 2019;17(11) Sama Fathy Mohamed , Nashwa Mohamed Aboalnasr1, Loai Mohamed El-Ahwal, Mamdouh Radwan El-Nahas ,Saharmohey El-Din Hazzaa. Department of internal medicine and Pathology, Tanta University, Faculty of Medicine, EGYPT.

42- The role of soluble urokinase plasminogen activator receptor (suPAR) in the diagnostics of diabetic foot infection.

Aslan S, Demirdal T, Erbak H, Aslan C. Infect Dis (Lond). 2020 Feb;52(2):107-113. doi:10.1080/23744235.2019.1688387. Epub 2019 Nov 12.PMID: 31713451

43- Elevation of serum procalcitonin (sPCT) in a non-infected patient:
diabetes mellitus as a neglected cause of high sPCT values:

Minerva Anestesiologica 2020 April;86(4):465-6 DOI: 10.23736/S0375-9393.19.14180-6 Chiara ROBINO 1 *,Christian A. COMPAGNONE, Federico POZZI, Francesco CURTO, Arturo CHIEREGATO

44- The predictive value of procalcitonin for early detection of infection in elderly type 2 diabetes mellitus.

J Infect Chemother 2020 Apr;26(4):343-348. doi:10.1016/j.jiac.2019.10.015. Epub 2019 Nov 15. Wei Lin¹, Huibin Huang¹, Junping Wen¹, Gang Chen¹, Xingsheng Lin², Songchang Shi³